March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Expression of Extracellular Matrix Proteins in Response to Thrombospondin-1 and -2 in Human Trabecular Meshwork Cells: Implications for Primary Open Angle Glaucoma
Author Affiliations & Notes
  • Stephnie M. Kennedy
    Eye & Vision Science, University of Liverpool, Liverpool, United Kingdom
  • Ian Grierson
    Eye & Vision Science, University of Liverpool, Liverpool, United Kingdom
  • Anshoo Choudhary
    Eye & Vision Science, University of Liverpool, Liverpool, United Kingdom
  • Footnotes
    Commercial Relationships  Stephnie M. Kennedy, None; Ian Grierson, MSD (F), Polyphotonix, UK (F); Anshoo Choudhary, None
  • Footnotes
    Support  International Glaucoma Association
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 3258. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Stephnie M. Kennedy, Ian Grierson, Anshoo Choudhary; Expression of Extracellular Matrix Proteins in Response to Thrombospondin-1 and -2 in Human Trabecular Meshwork Cells: Implications for Primary Open Angle Glaucoma. Invest. Ophthalmol. Vis. Sci. 2012;53(14):3258.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Biochemical and morphological changes within the trabecular meshwork (TM) and its extracellular matrix (ECM) are associated with impaired aqueous humour outflow resistance in primary open angle glaucoma (POAG). There is an increase in the ECM components, including collagen IV, laminin and fibronectin. This may represent a disruption in the normal turnover of ECM which is influenced by transforming growth factor-beta (TGFβ) and matrix metalloproteinases (MMP). Thrombospondins (TSP)-1 and -2 are expressed in the TM and modulate cell-matrix interactions. TSP-1 is up-regulated by TGFβ and TSP-2 mediates MMP-2 and -9 activities. We have previously identified that TSP-2 is expressed in the TM and is up-regulated by TGFβ and Dexamethasone, coinciding with a decrease in MMP-2 levels. This study aims to determine the role of TSP-2 on the expression of ECM proteins by human TM cells.

Methods: : Non-glaucomatous (NTM5) and glaucomatous (GTM3) human TM cell lines were treated with 2μg/ml TSP-2 and -1 recombinant human protein for seven days. Expression of fibronectin and collagen IV protein and mRNA levels were evaluated by western blotting and qPCR techniques, respectively.

Results: : GTM3 and NTM5 cells expressed fibronectin and collagen IV at the protein and mRNA level. GTM3 cells showed a 3.2 and 1.4 fold increase in fibronectin and collagen IV protein levels under untreated conditions, compared to the NTM5 cell line. Fibronectin protein levels were further increased in the GTM3 cells following treatment with 2μg/ml TSP-2, showing a 6.3 and 1.9 fold increase compared to NTM5 and GTM3 controls, respectively. TSP-1 treatment did not increase fibronectin levels in either the NTM5 or the GTM3 cell line. Collagen IV protein levels in GTM3 cells were increased in TSP-2 and TSP-1 treated samples showing a 1.6 and 1.2 fold increase respectively, compared to untreated NTM5 control samples. Collagen IV mRNA levels were increased in GTM3 TSP-2 treated samples, whilst fibronectin mRNA levels did not change, compared to untreated GTM3 controls.

Conclusions: : These data suggest that the TSP-2 increases the expression of fibronectin and collagen IV levels in the ECM of glaucomatous TM cells, relative to TSP-1. Given that TSP-2 is expressed in the TM and is upregulated in POAG and by TGFβ it has a potential role in the pathogenesis of glaucoma and may serve as a future therapeutic target in the management of POAG.

Keywords: outflow: trabecular meshwork • extracellular matrix • intraocular pressure 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×